Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression

Future Oncol. 2023 Feb;19(4):279-287. doi: 10.2217/fon-2022-0893. Epub 2023 Mar 14.

Abstract

Aim: The aim of this meta-regression was to assess the impact of mean/median age, mean/median tumor size, percentage of males in total sample, and total sample size on the comparative effectiveness of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT). Methods: Ten studies reporting on the composite outcome of overall survival and local control were included. Results: A significant relationship was found between age and overall survival at 1 and 2 for both RFA and SBRT. A significant relationship was noted also between age and local control at 1 and 2 years for RFA. Conclusion: Patients treated with SBRT had a wider range of tumor sizes and larger tumor sizes; no relationship was observed between tumor size and overall survival or local control by SBRT.

Keywords: hepatocellular carcinoma; local control; meta-regression; radiofrequency ablation; stereotactic body radiation therapy.

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Carcinoma, Hepatocellular* / radiotherapy
  • Carcinoma, Hepatocellular* / surgery
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / radiotherapy
  • Liver Neoplasms* / surgery
  • Male
  • Radiofrequency Ablation* / adverse effects
  • Radiosurgery* / adverse effects